These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20693523)

  • 1. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
    Wilens TE; Hammerness PG; Biederman J; Kwon A; Spencer TJ; Clark S; Scott M; Podolski A; Ditterline JW; Morris MC; Moore H
    J Clin Psychiatry; 2005 Feb; 66(2):253-9. PubMed ID: 15705013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G; Besag FM
    Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.
    Westover AN; Halm EA
    BMC Cardiovasc Disord; 2012 Jun; 12():41. PubMed ID: 22682429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
    Batra AS; Alexander ME; Silka MJ
    Pediatr Cardiol; 2012 Mar; 33(3):394-401. PubMed ID: 22298228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder.
    Olfson M; Huang C; Gerhard T; Winterstein AG; Crystal S; Allison PD; Marcus SC
    J Am Acad Child Adolesc Psychiatry; 2012 Feb; 51(2):147-56. PubMed ID: 22265361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
    Kratochvil CJ
    Am J Psychiatry; 2012 Feb; 169(2):112-4. PubMed ID: 22318789
    [No Abstract]   [Full Text] [Related]  

  • 18. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.